Skip to main content
Equibles
SPRY logo

SPRY · ARS Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track SPRY — free

Use SPRY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SPRY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.22 -0.17 (-3.15%) At close · Sep 9
Russell 2000 member Rebalance outlook locked
Market Cap
$558.89M
Shares
99.45M

ARS Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for ARS Pharmaceuticals, Inc. (SPRY), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲4900% $500,000 −$12.52M '24 Q2 24-08-09 · $2.07M −$19.13M '24 Q3 24-11-13 · $86.58M $49.93M '24 Q4 25-03-20 · $7.97M −$33.94M '25 Q1 25-05-14 ▲3043.4% $15.72M −$44.88M '25 Q2 25-08-13 ▲1471.6% $32.50M −$51.15M '25 Q3 25-11-10 ▼67.6% $28.09M −$41.32M '25 Q4 26-03-09 ▲184.5% $22.68M −$60.62M '26 Q1 26-05-15 LATEST ▲114.2% $33.66M −$62.34M '26 Q2 26-08-13
Earnings call
FY26 · Q2
2026-08-13
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
Positive tone Strategic shift to provider-focused commercial execution NEPI market share performance Cost discipline and path to profitability
Revenue
$33.66M
▲ 114.2% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call
Revenue
$22.68M
▲ 184.5% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-09
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
Positive tone Neffy clinical profile and real-world data Direct-to-consumer campaign and patient engagement Payer access and prior authorization
Revenue
$28.09M*
▼ 67.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
Confident tone U.S. neffy revenue growth International expansion Get neffy On Us virtual prescribing program
Revenue
$32.50M
▲ 1471.6% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
Confident tone neffy U.S. commercial momentum and revenue growth Payer access and prior authorization progress DTC advertising campaign
Revenue
$15.72M
▲ 3043.4% YoY
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
Confident tone neffy Commercial Launch and Revenue Growth neffy Experience Program and Physician Adoption Pediatric Dose (1 mg) Approval
Revenue
$7.97M
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Call Transcript
Confident tone neffy launch trajectory Payer coverage and prior authorization Pediatric label expansion
Revenue
$86.58M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
Confident tone neffy U.S. launch progress Physician adoption and education International partnerships and licensing
Revenue
$2.07M
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
ARS Pharmaceuticals, Inc. (SPRY) Q2 2024 Earnings Call
Revenue
$500,000
▲ 4900% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
ARS Pharmaceuticals, Inc. (SPRY) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–10 of 10 earnings calls
Key facts CIK 1671858 CUSIP 82835W108 13F (30d) 134 filings 134 filers Visit website Investor relations